-
公开(公告)号：US09266924B2
公开(公告)日：2016-02-23
申请号：US13641947
申请日：2011-04-20
申请人： Oliver Demmer , Horst Kessler , Hans-Jürgen Wester , Margret Schottelius , Ingrid Dijkgraaf , Andreas Konard Buck
发明人： Oliver Demmer , Horst Kessler , Hans-Jürgen Wester , Margret Schottelius , Ingrid Dijkgraaf , Andreas Konard Buck
CPC分类号： C07K7/64 , A61K51/088
摘要： The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18F-benzoyl residue.
摘要翻译： 本发明尤其涉及具有式（I）结构的化合物或其药学上可接受的盐，其中Xaa1至Xaa4彼此独立，任选N-烷基化天然或非天然氨基酸，R为 H或甲基，L是连接体部分，Ar是包含芳族部分的间隔基，D包括，优选i）有机络合剂和可检测标记的组合; 或ii）可检测标记，有机络合剂或活性物质，所述活性物质特别选自细胞毒性剂，脂质，糖，糖结合物，糖衍生物，蛋白质及其组合，条件是-L-Ar- D不包含18 F-苯甲酰残基。
-
公开(公告)号：US20130129622A1
公开(公告)日：2013-05-23
申请号：US13641947
申请日：2011-04-20
申请人： Oliver DEMMER , Horst KESSLER , Hans-Jürgen WESTER , Margret SCHOTTELIUS , Ingrid DIJKGRAAF , Andreas Konard BUCK
发明人： Oliver DEMMER , Horst KESSLER , Hans-Jürgen WESTER , Margret SCHOTTELIUS , Ingrid DIJKGRAAF , Andreas Konard BUCK
CPC分类号： C07K7/64 , A61K51/088
摘要： The present invention, among others, relates to a compound having a structure according to formula (I) or a pharmaceutically acceptable salt thereof, wherein Xaa1 to Xaa4 are independently of each other, an optionally N-alkylated natural or unnatural amino acid, R is H or methyl, L is a linker moiety, Ar is a spacer comprising an aromatic moiety, and D comprises, preferably is i) a combination of an organic complexation agent and a detectable label; or ii) a detectable label, an organic complexation agent or an active substance, said active substance particularly being selected from cytotoxic agents, lipids, sugars, sugar conjugates, sugar derivatives, proteins and combinations thereof, with the proviso that -L-Ar-D does not comprise a 18F-benzoyl residue.
摘要翻译： 本发明尤其涉及具有式（I）结构的化合物或其药学上可接受的盐，其中Xaa1至Xaa4彼此独立，任选N-烷基化天然或非天然氨基酸，R为 H或甲基，L是连接体部分，Ar是包含芳族部分的间隔基，D包括，优选i）有机络合剂和可检测标记的组合; 或ii）可检测标记，有机络合剂或活性物质，所述活性物质特别选自细胞毒性剂，脂质，糖，糖结合物，糖衍生物，蛋白质及其组合，条件是-L-Ar- D不包含18 F-苯甲酰残基。
-
公开(公告)号：US20090324497A1
公开(公告)日：2009-12-31
申请号：US12556698
申请日：2009-09-10
CPC分类号： A61K51/088 , A61K51/083
摘要： Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.
摘要翻译： 提供了用于核医学诊断和治疗应用的改善的sst-受体结合肽配体。 改进的配体含有天然或非天然氨基酸或在N-末端或C-末端或两末端修饰的拟肽结构，碳水化合物单元和螯合剂或修饰基团以提供放射性同位素结合的络合 或持有放射性同位素。 Sst-或SSTR-受体结合肽配体还可以含有一个或多个任选地偶联肽，和/或糖部分和/或螯合剂和/或假体基团的多官能连接基团。 通过血液系统向哺乳动物施用配体时，配体提供了非碳水化合物配体上改善的可用性，清除动力学，sst受体靶向和内化。
-
公开(公告)号：US08575100B2
公开(公告)日：2013-11-05
申请号：US12556698
申请日：2009-09-10
CPC分类号： A61K51/088 , A61K51/083
摘要： Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.
摘要翻译： 提供了用于核医学诊断和治疗应用的改善的sst-受体结合肽配体。 改进的配体含有天然或非天然氨基酸或在N-末端或C-末端或两末端修饰的拟肽结构，碳水化合物单元和螯合剂或修饰基团以提供放射性同位素结合的络合 或持有放射性同位素。 Sst-或SSTR-受体结合肽配体还可以含有一个或多个任选地偶联肽，和/或糖部分和/或螯合剂和/或假体基团的多官能连接基团。 通过血液系统向哺乳动物施用配体时，配体提供了非碳水化合物配体上改善的可用性，清除动力学，sst受体靶向和内化。
-
公开(公告)号：US07589061B2
公开(公告)日：2009-09-15
申请号：US10475696
申请日：2002-04-23
CPC分类号： A61K51/088 , A61K51/083
摘要： Improved sst-receptor binding peptidic ligands for diagnostic and therapeutic applications in nuclear medicine are provided. The improved ligands contain either natural or unnatural amino acids or peptidomimetic structures that are modified at either the N-terminal or the C-terminal end or at both termini, a carbohydrate unit and a chelator or prosthetic group to provide a complexation of a radioisotope binding or holding the radioisotope. The sst- or SSTR-receptor binding peptidic ligands may also contain one or more multifunctional linker units optionally coupling the peptide, and/or the sugar moiety and/or the chelator and/or the prosthetic group. Upon administering the ligand to a mammal through the blood system the ligand provides improved availability, clearance kinetics, sst-receptor targeting and internalization over the non-carbohydrated ligands.
摘要翻译： 提供了用于核医学诊断和治疗应用的改善的sst-受体结合肽配体。 改进的配体含有天然或非天然氨基酸或在N-末端或C-末端或两末端修饰的拟肽结构，碳水化合物单元和螯合剂或修饰基团以提供放射性同位素结合的络合 或持有放射性同位素。 Sst-或SSTR-受体结合肽配体还可以含有一个或多个任选地偶联肽，和/或糖部分和/或螯合剂和/或假体基团的多官能连接基团。 通过血液系统向哺乳动物施用配体时，配体提供了非碳水化合物配体上改善的可用性，清除动力学，sst受体靶向和内化。
-
-
-
-
搜索结果
5 条记录 (耗时 0.012 秒)
